A Phase Ib Multi-Cohort Trial of MK-3475 (pembrolizumab) in Subjects with Hematologic Malignancies
ID Number 16-1672Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to evaluate the safety, tolerability and effectiveness of an experimental drug called MK-3475 (pembrolizumab) and to evaluate disease response rate to MK-3475 (pembrolizumab). An experimental drug is not approved by the UNited States FDA for use except in research studies. MK-3475 has been approved for use in certain types of adult melanoma and lung cancer however it has not been approved in any other cancers.
Recruiting Patients: Yes